About the company

Driven by a deep commitment to life, a dedicated team of patients and scientists is working for a future with unlimited movement and freedom. With relentless passion and innovation, they push the boundaries of what is possible. They are pioneering breakthrough therapies for chronic degenerative diseases. Their mission is to develop first-class technology with transformative potential, addressing critical unmet needs in rheumatology and orthopaedics. United by a shared vision, they are paving the way for the next generation of healthcare solutions.

‍

Why invest

Osteoarthritis affects 650 million people worldwide and causes pain, inflammation and reduced mobility. A groundbreaking injectable therapeutic device has been developed that addresses the cause of the disease, rather than just alleviating symptoms. This first-class solution offers a rapid market introduction with strong commercial potential and can revolutionize the treatment of osteoarthritis.

The device shows clear superiority over existing treatments, such as hyaluronic acid. Clinical studies show an 89% response rate with long-term effectiveness. With a clearly regulated process and a high medical need, this investment is financially very interesting.

‍

A unique investment opportunity

The device operates via a three-phase mechanotransductive action that activates the immune system and promotes recovery, with lasting clinical benefits. Safety has been confirmed in preclinical animal studies. Trials with 81 horses showed excellent results, keeping them crippled for more than a year.

Regulatory approval is underway in Europe and the US. The EU Phase I-II trial with 100 patients is testing safety and tolerability, with a market launch scheduled for mid-2027. In the US, phase III studies with 200 patients and a superiority trial with 300 patients are scheduled for 2026-2027. With EU approval in 2027 and a market launch in the US in 2028, this breakthrough treatment will dominate the osteoarthritis market and grow sales strongly.

‍

The investment

The company is seeking €1 million via a convertible loan (CLA).

‍

Interested?

Get in touch to discuss investment opportunities in this medical biotechnology.